Characteristics of patients with objective response
. | Sex/age, y . | . | No. prior systemic treatment/auto . | . | . | Preparative regimen/graft . | Day 15-30/60-90 chimera . | aGVHD grade/day . | cGVHD grade/day . | DL 1 day . | Response . | . | Secondary progression/day . | . | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| UPN . | . | Pathology . | . | Status . | Metastasis sites . | . | . | . | . | . | Onset/day . | Max/day . | . | Outcome . | |
| 10 | F/43 | Melanoma | 3/0 | Stable | Liver/pulmonary | 10 mg/kg ATG/BM | ND/100% | 0 | 0 | 140 | PR/60 | -56%/90 | Yes/140 | Death, 665 d | |
| 31 | F/60 | Ovarian Ca | 3/1 | Stable | Peritoneal/CA12.5 | 2.5 mg/kg ATG/PBSC | 100%/100% | III/34 | Lim/100 | NA | PR/30 | -45%/30 | Yes/120 | Death, 332 d | |
| 34 | M/45 | RCC | 1/0 | Stable | Pulmonary | 2.5 mg/kg ATG/PBSC | 100%/100% | IV/38 | Ext/100 | NA | PR/90 | -50%/120 | Yes/330 | Death, 360 d | |
| 39 | F/53 | RCC | 1/0 | Stable | Pulmonary | 2.5 mg/kg ATG/PBSC | ND/100% | II/76 | Lim/100 | 620 | PR/150 | CR/270 | Yes/605 | Alive, 645 d | |
| 42 | F/54 | Breast Ca | 3/1 | Stable | Bone/CA15.3 | 2.5 mg/kg ATG/PBSC | ND/100% | 0 | Lim/100 | NA | CR/90 | CR/90 | Yes/310 | Alive, 615 d | |
| 43 | F/53 | Ovarian Ca | 4/1 | Stable | ADP/CA12.5 | 2.5 mg/kg ATG/PBSC | 100%/100% | 0 | Lim/140 | NA | PR/90 | -90%/270 | No | Alive in PR (ADP -90%; CA12.5, NL), 617 d | |
| 45 | F/32 | Breast Ca | 3/0 | Stable | Liver/mediastinal ADP | 2.5 mg/kg ATG/PBSC | >95%/100% | II/17 | Lim/180 | 150 | PR/30 | -60%/240 | No | Alive in PR (liver -60%), 591 d | |
| 51 | F/36 | Ovarian Ca | 4/2 | Stable | Pulmonary/parietal/CA12.5 | 2.5 mg/kg ATG/PBSC | ND/100% | 0 | Lim/110 | NA | PR/60 | -75%/150 | Yes/262 | Alive, 428 d | |
. | Sex/age, y . | . | No. prior systemic treatment/auto . | . | . | Preparative regimen/graft . | Day 15-30/60-90 chimera . | aGVHD grade/day . | cGVHD grade/day . | DL 1 day . | Response . | . | Secondary progression/day . | . | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| UPN . | . | Pathology . | . | Status . | Metastasis sites . | . | . | . | . | . | Onset/day . | Max/day . | . | Outcome . | |
| 10 | F/43 | Melanoma | 3/0 | Stable | Liver/pulmonary | 10 mg/kg ATG/BM | ND/100% | 0 | 0 | 140 | PR/60 | -56%/90 | Yes/140 | Death, 665 d | |
| 31 | F/60 | Ovarian Ca | 3/1 | Stable | Peritoneal/CA12.5 | 2.5 mg/kg ATG/PBSC | 100%/100% | III/34 | Lim/100 | NA | PR/30 | -45%/30 | Yes/120 | Death, 332 d | |
| 34 | M/45 | RCC | 1/0 | Stable | Pulmonary | 2.5 mg/kg ATG/PBSC | 100%/100% | IV/38 | Ext/100 | NA | PR/90 | -50%/120 | Yes/330 | Death, 360 d | |
| 39 | F/53 | RCC | 1/0 | Stable | Pulmonary | 2.5 mg/kg ATG/PBSC | ND/100% | II/76 | Lim/100 | 620 | PR/150 | CR/270 | Yes/605 | Alive, 645 d | |
| 42 | F/54 | Breast Ca | 3/1 | Stable | Bone/CA15.3 | 2.5 mg/kg ATG/PBSC | ND/100% | 0 | Lim/100 | NA | CR/90 | CR/90 | Yes/310 | Alive, 615 d | |
| 43 | F/53 | Ovarian Ca | 4/1 | Stable | ADP/CA12.5 | 2.5 mg/kg ATG/PBSC | 100%/100% | 0 | Lim/140 | NA | PR/90 | -90%/270 | No | Alive in PR (ADP -90%; CA12.5, NL), 617 d | |
| 45 | F/32 | Breast Ca | 3/0 | Stable | Liver/mediastinal ADP | 2.5 mg/kg ATG/PBSC | >95%/100% | II/17 | Lim/180 | 150 | PR/30 | -60%/240 | No | Alive in PR (liver -60%), 591 d | |
| 51 | F/36 | Ovarian Ca | 4/2 | Stable | Pulmonary/parietal/CA12.5 | 2.5 mg/kg ATG/PBSC | ND/100% | 0 | Lim/110 | NA | PR/60 | -75%/150 | Yes/262 | Alive, 428 d | |
UPN indicates unique patient number; DLI, donor lymphocyte infusion; ATG, antithymocyte globulin; BM, bone marrow; ND, not done; PR, partial response; Ca, carcinoma; PBSC, peripheral blood stem cell; Lim, limited; NA, not applicable; RCC, renal cell carcinoma; Ext, extensive; CR, complete response; ADP, adenopathy; and NL, normal.